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ABSTRACT
Quantitativecomputedtomography(QCT)canestimatevolumetricbonemineraldensity(vBMD)anddistinguishtrabecularfromcortical
bone. Few comprehensive studies have examined correlates of vBMD in older men. This study evaluated the impact of demographic,
anthropometric, lifestyle, and medical factors on vBMD in 1172 men aged 69 to 97 years and enrolled in the Osteoporotic Fractures in
Men Study (MrOS). Peripheral quantitative computed tomography (pQCT) was used to measure vBMD of the radius and tibia. The
multivariable linear regression models explained up to 10% of the variance in trabecular vBMD and up to 9% of the variance in cortical
vBMD. Age was not correlated with radial trabecular vBMD. Correlates associated with both cortical and trabecular vBMD were age ( ),
caffeine intake ( ), total calcium intake (þ), nontrauma fracture ( ), and hypertension (þ). Higher body weight was related to greater
trabecular vBMD and lower cortical vBMD. Height ( ), education (þ), diabetes with thiazolidinedione (TZD) use (þ), rheumatoid arthritis
(þ), using arms to stand from a chair ( ), and antiandrogen use ( ) were associated only with trabecular vBMD. Factors associated only
with cortical vBMD included clinic site ( ), androgen use (þ), grip strength (þ), past smoker ( ), and time to complete five chair stands
( ). Certain correlates of trabecular and cortical vBMD differed among older men. An ascertainment of potential risk factors associated
with trabecular and cortical vBMD may lead to better understanding and preventive efforts for osteoporosis in men.  2010 American
Society for Bone and Mineral Research.
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Introduction
T
here is growing recognition that osteoporosis and fractures
in older men are significant public health problems that
contribute to disability and premature death.
(1) Osteoporosis is
defined as a systemic bone disease characterized by low bone
mass and mircoarchitectural deterioration of bone tissue, with a
subsequent increase in bone fragility and susceptibility to
fracture.
(2) Low bone mineral density (BMD) is an important risk
factor for fractures in men. Men over the age of 50 have a 13%
estimated risk of developing an osteoporotic fracture.
(3)
A major limitation of dual-energy X-ray absorptiometry (DXA)
is its inability to distinguish cortical and trabecular bone. Bones
tend to differ in their composition of trabecular and cortical
bone. For example, the spine is primarily trabecular bone.
(4)
Therefore, identifying correlates of trabecular bone can lead to a
better understanding of what factors might be associated
with spine fracture. Also, DXA provides a measurement in
only two dimensions and thus reports an areal BMD (aBMD).
Bones of larger width and length tend to have greater depth (eg,
in men compared with women), and since bone depth is not
accounted for in DXA scanning, reliance on aBMD inherently
ORIGINAL ARTICLE J JBMR
Received in original form September 6, 2009; revised form October 30, 2009; accepted December 15, 2009. Published online December 21, 2009.
Address correspondence to: Kamil E Barbour, MPH, Department of Epidemiology, Graduate School of Public Health, 130N Bellefield Avenue, Pittsburgh, PA 15213,
USA. E-mail: barbourk@edc.pitt.edu
Journal of Bone and Mineral Research, Vol. 25, No. 5, May 2010, pp 1017–1028
DOI: 10.1002/jbmr.6
 2010 American Society for Bone and Mineral Research
1017underestimates bone density.
(5) Volumetric BMD (vBMD) has
been showntobeastronger predictor ofvertebralfracturesthan
aBMD in some studies.
(6,7) Quantitative computed tomography
(QCT) assesses vBMD and distinguishes cortical from trabecular
bone.
(8) The correlates of DXA-measured BMD have been well
established in men.
(1,9–13) However, few studies have examined
the correlates of vBMD, especially in older men.
(8,11) The aim of
this study was to identify correlates of trabecular and cortical
vBMD using peripheral QCT (pQCT) and examine whether they
differ.
Materials and Methods
Study population
From March 2000through April 2002, 5995men aged 65 years or
older were recruited using population-based listings from six US
clinical sites to participate in the Osteoporotic Fractures in Men
Study (MrOS).
(14,15) pQCT measurements were obtained at the
Minneapolis,MN,andMonongahelaValley,PA,studysitesduring
the second clinic visit between March 21, 2005, and April 11,
2006, for 1172 individuals (46.1% from MN and 53.9% from PA)
aged69 to97years.Theinstitutionalreview boardateachcenter
approved the study protocol, and written informed consent was
obtained from all the participants.
pQCT measurements
pQCT examinations were performed on the Sratec XCT scanner
series (2000 or 3000, Stratec, Inc., Pforzheim, Germany).
Trabecular vBMD of the radius and tibia was measured by
obtaining an ultradistal slice at 4% of the length of the ulna
proximal to the radial endplate and at 4% of the tibia length
proximal to the tibial endplate, respectively. Cortical vBMD of the
radius and tibia was measured by obtaining a distal slice at 33%
of the length of the ulna proximal to the radial endplate and at
33% of the tibia length proximal to the tibial endplate,
respectively. A scout view (an anatomic reference line for the
relative location of subsequent scans) was obtained prior to the
pQCT scan at the tibia and radius. Precise assessment of bone
mineral properties by pQCT was ensured by minimizing
participant movement. A quality assurance (QA) phantom scan
was used to monitor the stability of the pQCT scanner. A cross-
calibration check also was performed between the centers. The
European Forearm Phantom was scanned three times at each
site at 200, 100, and 50mg/mL, respectively. Voxel size was
0.5mm, and the scan speed was 25mm/s. To determine the
trabecular vBMD(mg/cm
3), all radius and tibia scans were
analyzed using identical parameters for contour findings and
separation of trabecular and cortical bone (contour mode 2,
T¼169mg/cm
3; peel mode 1, area¼45%). All proximal radius
and tibia shaft scans were analyzed using identical parameters
for contour finding and separation of total and cortical bone
(contour mode 2, T¼169mg/cm
3; cortmode 1, T¼710mg/cm
3)
to determine the vBMD of the cortical-rich bone compartment
(mg/cm
3). Coefficients of variation (CVs) were determined for
pQCT scans by replicating measurements on 15 subjects
(CV 2.1%).
(8)
Other measurements
Self-administered and interviewer-administered questionnaires
were used by trained clinical staff to obtain demographic,
medical, and lifestyle information from the participants.
Information on anthropometric measures, neuromuscular func-
tion, and medication use also was obtained at the clinic.
(14)
Information on covariates was obtained from visit 2, with the
exception of race/ethnicity, education, alcohol intake, calcium
and vitamin D intake, history of a nontrauma fracture after age
50, self-report of diabetes and fasting glucose level, whether a
subject ever had a gastrectomy, and testosterone injection use,
all of which was abstracted at baseline.
Race/ethnicity was based on self-declaration and included the
following categories: white, African American, Hispanic, Asian,
and other. The participants were divided into two categories of
education for analysis: greater than a high school education and
high school education or lower.
A calibrated balance-beam scale was used to measure weight
in kilograms. Participants had to wear indoor clothing and
remove their shoes when their weight was being measured.
Height was measured in meters using a Harpenden Stadiometer
(Dyfed, UK).
Gait speed (m/s) was determined as the time to complete a
6-m walk. Grip strength (kg) was measured twice using a
handheld Jamar dynamometer (Sammons Preston Rolyan,
Bolingbrook, IL, USA) and taking the average in both the right
and left arms.
(16) Time to complete five chair stands (seconds)
and ability to stand from a chair without using the arms (yes/no)
also were measured.
Lifestyle factors included self-report of smoking (current, past,
and never), alcohol intake (drinks/week), caffeine intake (mg/
day), and time spent walking (hours/day). Overall physical
activity also was measured by computing the physical activity
summaryscalefortheelderly(PASE).
(17)ThemodifiedBlockFood
Frequency Questionnaire was used to obtain dietary information
related to calcium and vitamin D intake over the past year.
(18)
Subjects were asked to report if they were ever told by a doctor
or health care provider that they had certain medical conditions,
including hypertension, stroke, myocardial infarction (MI), chronic
obstructive pulmonary disease (COPD), cancer, osteoporosis,
osteoarthritis (OA), hyperthyroidism, hypothyroidism, Parkinson’s
disease, and kidney stones.Men were classified as having diabetes
if they had glucose levels 126mg/dL (after a minimum of an
8-hour fast) at baseline, made a self-report of diabetes at baseline
or visit 2, or were taking insulin or hypoglycemic medications at
baseline or visit 2. Men with diabetes were further categorized as
havingahistoryofthiazolidinedione(TZD) versusnon-TZD use.We
areunabletodistinguishtype1and2diabetes.However,basedon
the older age of the participants and the shorter longevity
associated with type 1 diabetes for this birth cohort, it is likely that
nearly all have type 2 diabetes.
Participants were asked to bring all current (use within last
30 days) prescription and nonprescription medications with
them to clinic. Interviewers completed a medication history for
each participant, including name of medication and frequency
of use. All prescription medications recorded by the clinics
were stored in an electronic medications inventory database
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Each medication was matched to its ingredient(s) based on
the Iowa Drug Information Service (IDIS) Drug Vocabulary
(College of Pharmacy, University of Iowa, Iowa City, IA, USA).
(19)
Androgen use was defined as testosterone or dehydroepian-
drosterone (DHEA) use. Antiandrogen use included use of
flutamide or bicalutamide.
Statistical analysis
All statistical analyses were performed using the Statistical
Analysis System (SAS, Version 9.1, SAS Institute, Cary, NC, USA).
Analysis of variance (ANOVA) was used to compare the
unadjusted skeletal site-specific vBMD across age groups with
a test of trend and a Bonferroni adjustment for pairwise
comparisons. Linear regression analyses for age- and age- and
weight-adjustedmodelswereusedtoexaminetheassociationof
each correlate with cortical and trabecular vBMD at the
radius and tibia. The associations were expressed as a 1 unit
increase for categorical variables and 1 standard deviation (SD)
increase for continuous variables. The formula used to calculate
the percent difference in vBMD per unit change of predictor
variable was (b coefficient unit/mean vBMD) 100. The
corresponding confidence intervals were calculated as [(b
coefficient 1.96 standard error) (unit)/(mean vBMD)] 100.
Variableswithapvalueoflessthan.10fromtheage-andweight-
adjusted models were entered into the multivariable models. We
excluded men from the multivariable analysis who reported to
be taking osteoporosis medication (n¼42) or self-reported
osteoporosis (n¼41) because these men, on average, had
markedly lower vBMD values compared with nonusers. For the
multivariable models, we used the backward elimination
procedure at each skeletal site with age forced in the models.
A stepwise selection procedure produced similar results. Multi-
collinearity was assessed using the variance inflation factor (VIF).
An additional analysis examined whether correlates of vBMD
differed after excluding nonwhite men in the multivariable
analysis. To further understand whether the association between
diabetesandvBMDisindependentormodifiedbyhypoglycemic
medication use, we performed secondary multivariable analyses
with and without, taking into account diabetic medications. For
the diabetic medications parameter, men were categorized as
nonusers of hypoglycemic medication, users of insulin or
hypoglycemic agents without a history of TZD use, and use of
any TZD either with or without additional hypoglycemic
medications.
Results
The study population consisted of whites (97.9%), African
Americans (1.4%), Asians (0.2%), Hispanics (0.3%), and others
(0.2%). The average age of the men was 77.2 5.1 years, and
61.9% had higher than a high school education. The mean
and SD values for trabecular and cortical vBMD were 197 46
and 1159 34mg/cm
3, respectively, for the radius and were
231 41 and 1136 35mg/cm
3, respectively, for the tibia.
Tables 1 and 2 show the age- and age- and weight-adjusted
models. These results were used to build the multivariable
models.
Pairwise comparisons and trend for vBMD by age
Figures 1 and 2 show the unadjusted cross-sectional age-related
patterns at each site. Trabecular vBMD at the radius did not differ
by age (p¼.483 for trend). The test of linear trend for tibial
trabecular vBMD was statistically significant (p¼.002). Partici-
pants aged 69 to 74 years had 4.1% and 5.7% greater trabecular
vBMD at the tibia than those aged 80 to 84 years (p¼.022) and
85 ormore years (p¼.030),respectively. Cortical vBMD variedby
age at both skeletal sites (p<.001 for trend). At the radius, men
aged 69 to 74 years had 0.7% and 1.8% greater cortical vBMD
than those aged 80 to 84 years (p¼.008) and 85 or more years
(p<.001), respectively. Radial cortical vBMD was 1.5% greater
among participants aged 75 to 79 years than men aged 85 or
more years (p<.001). Also, men aged 80 to 84 years had 1.0%
greater radial cortical vBMD than those aged 85or more years
(p¼.021). At the tibia, men aged 69 to 74 years had 0.9% and
1.1% greater cortical vBMD than those aged 80 to 84 years
(p¼.001) and 85 or more years (p¼.005), respectively. Finally,
those aged 75 to 79 years had 0.7% greater tibial cortical vBMD
than men aged 80 to 84 years (p¼.035).
Multivariable models
The results of the multivariable analyses are summarized in
Table3.Attheradius,multivariablemodelsexplained4%and9%
of the overall variance for trabecular and cortical vBMD,
respectively. The models for cortical and trabecular vBMD at
the tibia site explained 8% and 10% of the overall variance. An
increase of 1 SD (5.1 years) of age was significantly correlated
with lower vBMD at all sites with the exception of trabecular
vBMD at the radius. Having greater than a high school education
was correlated with 3.0% greater trabecular vBMD of the tibia.
Men from Monongahela Valley had  0.8% lower cortical vBMD
than those from Minneapolis. A 1 SD (13.5kg) increase in weight
was associated with 2.3% greater tibial trabecular vBMD.
However, this increase in weight was correlated with lower
cortical vBMD of the radius ( 0.5%) and tibia ( 0.3%). A 1 SD
(6.9cm) increase in height was associated with lower trabecular
vBMD at the tibia ( 1.6%). A 1 SD (259.3mg/day) increase in
caffeine consumption was associated with lower cortical vBMD
of the radius. Caffeine intake also was associated with lower
trabecular and cortical vBMD of the tibia. A 1 SD (564.9mg/day)
increase in total calcium was associated with greater cortical and
trabecular vBMD at both skeletal sites. Past smokers had
significantly lower ( 0.4%) cortical vBMD of the radius than
individuals who had never smoked. History of a nontrauma
fracture was associated with lower trabecular and cortical vBMD
at both sites. Men who had diabetes and used TZD had greater
trabecular vBMD of the radius (9.3%) and tibia (8.0%) than those
with no diabetes. Having hypertension was correlated with
greater (4.9%) trabecular and cortical (0.6%) vBMD of the radius.
Rheumatoid arthritis was associated with a 5.3% greater
trabecular vBMD of the tibia. Androgen use was correlated with
greater cortical vBMD at both sites. Men who used antiandro-
gens had lower ( 24.9%) trabecular vBMD of the tibia. An
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CORRELATES OF TRABECULAR AND CORTICAL vBMD Journal of Bone and Mineral Research 1023increase of 1 SD (7.7kg) in grip strength was associated
with greater (0.3%) cortical vBMD of the radius. Each 1 SD
(3.4seconds) increase in time to complete five chair stands was
associated with lower ( 0.3%) cortical vBMD at the tibia. Men
who needed to use their arms to stand from a chair had lower
( 7.2%) trabecular vBMD of the tibia.
Secondary analyses
In the analysis that did not account for hypoglycemic medicat-
ion use, men identified as having diabetes did not differ
significantly by vBMD from men without diabetes. Insulin or
hypoglycemic medication use without TZD use was not
associated with vBMD. However, men who used TZDs had
significantly greater trabecular vBMD of the radius (8.9%) and
tibia (9.6%) than nonusers of antidiabetic medication. Finally,
exclusion of nonwhites from the multivariable analysis did not
change the correlates of vBMD that were identified at all sites.
Discussion
We characterized demographic, anthropometric, lifestyle, and
medical factors to understand their association with cortical and
trabecular vBMDamongoldermen. Uniquefeatures ofthisstudy
include large sample size of men, comprehensive nature of the
analyses, and ascertainment of correlates and outcome. Our
study results suggest that some correlates of trabecular vBMD
may differ from those of cortical vBMD.
Age was not associated with lower trabecular vBMD of the
radius, consistent with the findings of a previous study by Dalzell
and colleagues
(20) but contrary to the findings of Riggs and
colleagues,
(21,22) Reduction in trabecular vBMD has been shown
to occur before midlife (ages 20 to 49) in men and women and to
continue unabated through life.
(21–23) The mechanism for this
early onset of trabecular vBMD loss remains unknown. A
significant reduction in radial trabecular vBMD may have
occurred at a younger age for this population. However, our
results are cross-sectional comparisons across age groups, and
longitudinal studies are needed. Consistent with prior findings,
increasing age was associated with lower cortical vBMD.
(20–22,24)
In women, substantial cortical bone loss has been shown to
occur after midlife in association with menopause and estrogen
deficiency.
(25) However, cortical bone loss in men seems to
decreaseataconstantrateinyoungadulthooduntilaccelerating
late in life.
(22)
This study found a positive association between education
and trabecular vBMD. This correlation has not been reported
previously in men and may be a result of residual confounding.
Higher education may lead to the adoption of a better lifestyle
that could impact vBMD positively.
Body weight was associated with greater trabecular vBMD,
consistent with two previous studies.
(8,26) Several studies observed
a positive association between weight and aBMD.
(9,10,13) Larger
skeletal frames and greater muscle and body fat in heavy
individuals may increase the mechanical load on the skeleton,
promoting mineralization and structural adaptive responses that
can strengthen bone.
(27) However, body weight was associated
with lower cortical vBMD similar to two previous studies.
(8,28) It is
also possible that mechanical factors or differences in bone
geometry may explain these findings. Paradoxically, increased
mechanical loads can lead to bone microdamage, increased
bone turnover, and a transient reduction in cortical vBMD.
(29)
Also, overweight individuals may adapt by increasing periosteal
bone diameter, requiring lower cortical density to maintain the
same strength.
(30) Additional studies are needed to fully
understand these relationships.
Similar to our findings, the Tobago Bone Health Study
reported a negative association between height and trabecular
vBMD, consistent with the negative association on femoral neck
aBMD.
(1,8) Taller individuals are known to experience greater
heightlossandhavebeenshowntobeatahigherriskoffracture
than others.
(31–33)
Several lifestyle and dietary factors were correlated with vBMD.
Higher caffeine intake was associated with lower cortical and
trabecular vBMD, similar to a previous study that examined
calcaneus BMD in a young population of primarily white men.
(26)
However, some studies on aBMD in older white men
(1,9,10) and
another on vBMD in African men found no association.
(8) Caffeine
may reduce BMD by decreasing intestinal calcium absorption, but
it also may be a marker for lower calcium consumption in our
population (r¼ 0.1, p¼.059).
(34) Our study found that past
smokers had significantly lower cortical vBMD. A study on men of
African descent found a negative correlation among smokers for
trabecular and cortical vBMD,
(8) and another found a negative
association among smokers for trochanter aBMD in a cohort of
primarily elderly white men.
(10) However, the Gothenburg
Fig. 1. Trabecular vBMD by age group.
Fig. 2. Cortical vBMD by age group.
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significant association between smoking and vBMD.
(35) Smoking
has been shown to have a negative effect on BMD by decreasing
calcium absorption or by inhibiting the proliferation of osteo-
progenitor cells.
(36,37) Total calcium use was associated with
greater trabecular and cortical vBMD, which is consistent with
studiesonaBMD
(1,12,54) and vBMD
(25) inwhite men and anotherin
African men.
(8) An adequate intake of calcium is needed to
ameliorate the progressive loss of bone with age.
(38)
History of fracture was one of the strongest factors related to
lower trabecular and cortical vBMD at both skeletal sites and is
consistent with studies of aBMD
(1,13) and vBMD
(23,39,40) in men.
Diabetic men using TZD had greater trabecular vBMD at both
skeletal sites. Greater weight among TZD users compared with
diabetic men with no TZD use (95.3 versus 88.5kg, p¼.013) and
nondiabetic men (95.3 versus 82.9kg, p<.001) may have
contributed to these findings. Prior research shows a negative
association between TZD use and aBMD in diabetic men and
women,
(40,41) consistent with the observation that TZDs increase
bone marrow adiposity, resulting in a decrease in osteoblasto-
genesis, and possibly affect the aromatase pathway, leading to
a reduction in estrogen production.
(42,43) Our findings are
surprising and need to be replicated in other studies.
Hypertension was associated with higher trabecular and cortical
vBMD, comparable with previous studies for aBMD
(1) in white
men and vBMD in men of African heritage.
(11) However, Orwoll
and colleagues reported that hypertension was related to lower
aBMD in a largely white population of men aged 60 years and
older.
(13) A positive association may arise from confounding by
the use of certain medications such as thiazide (TZ) diuretics,
which may increase BMD owing to their ability to improve
calcium retention.
(9,44,45) However, excluding TZ diuretic users
did not change the association, making it likely that other factors
were involved. Rheumatoid arthritis was unexpectedly asso-
ciated with trabecular of the tibia and may have occurred by
chance. An earlier report using the same cohort found no
Table 3. Percent Difference in vBMD per Unit Change of Each Correlate Using the Backward Elimination Procedure for Multiple Linear
Regression Models
Variable Unit
Percent change in vBMD per unit change (95% CI)
Radius Tibia Radius Tibia
Trabecular vBMD
a Trabecular vBMD
b Cortical vBMD
c Cortical vBMD
d
n 1058 1065 1048 990
Demographics
Age (years) 5.1  0.6 ( 1.9, 0.8)  1.2 ( 2.3,  0.1)  0.4 ( 0.6, 0.2)  0.4 ( 0.6,  0.2)
>High school education — 3.0 (0.9,5.2) — —
Site (Monongahela Valley, PA) — — —  0.8 ( 1.2,  0.4)
Anthropometrics —
Weight (kg) 13.5 — 2.3 (1.1, 3.6)  0.5 ( 0.7, 0.3)  0.3 ( 0.5,  0.1)
Height (m) 6.9 —  1.6 ( 2.8,  0.4) — —
Lifestyle
Caffeine intake (mg/day) 259.3 —  1.2 ( 2.2,  0.2)  0.2 ( 0.4,  0.1)  0.2 ( 0.4,  0.1)
Total calcium (mg/day) 564.9 2.5 (1.1, 3.9) 1.5 (0.5, 2.6) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4)
Past smoker — —  0.4 ( 0.8,  0.1) —
Medical history
Nontrauma fracture (any)  7.2 ( 11.1,  3.4)  7.6 ( 10.5,  4.8)  0.8 ( 1.3,  0.3)  0.8 ( 1.4,  0.3)
Hypertension 5.0 (2.2, 7.8) — 0.6 (0.2, 0.9) —
Diabetes and TZD use 9.3 (1.5, 17.0) 8.0 (2.2, 13.7) — —
Rheumatoid arthritis — 5.3 (0.9, 9.6) — —
Medications
Androgens — — 3.0 (0.9, 5.0) 2.7 (0.4, 5.0)
Antiandrogen —  24.9 ( 43.9,  5.9) — —
Neuromuscular function
Grip strength (kg) 7.7 — — 0.3 (0.1, 0.5) —
Chair stands (s) 3.4 — — —  0.3 ( 0.5,  0.1)
Stands with arms —  7.2 ( 11.0,  3.4) — —
r
2 0.04 0.10 0.09 0.08
aTotal calcium intake (mg/day), nontrauma fracture (any), hypertension, and diabetes and TZD use were significant in the model.
bAge, weight, height, education, caffeine intake (mg/day), total calcium intake (mg/day), nontrauma fracture (any), diabetes and TZD use, rheumatoid
arthritis, antiandrogens, and stands with arms were significant in the model.
cAge, weight (kg), caffeine intake (mg/day), total calcium intake (mg/day), past smoker, nontrauma fracture (any), hypertension, androgens, and grip
strength (kg) were significant in the model.
dAge, weight (kg), site, caffeine intake (mg/day), total calcium intake (mg/day), nontrauma fracture (any), androgens, and time to complete five chair
stands (s) were significant in the model.
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(1) while
another study found a negative correlation among older white
men.
(13) Anti-inflammatory medications such as nonsteroidal
anti-inflammatory drugs (NSAIDs) have been shown to increase
BMD.
(1,46) Excluding men who used NSAIDs attenuated the
association, making it no longer significant.
Androgen-replacement therapy was associated with higher
cortical vBMD at both skeletal sites, consistent with past findings
on trabecular vBMD
(47) and aBMD
(48) at the lumbar spine. High
androgen levels may help to maintain BMD by promoting
osteoblast differentiation and inhibiting osteoclast recruit-
ment.
(49) The very low prevalence (0.6%) of androgen users
likely contributed to the null finding for trabecular vBMD.
Antiandrogen use was independently related to lower trabecular
vBMD ofthe tibia. TheTobago BoneHealth Study alsofound that
antiandrogen users had significantly lower cortical vBMD at the
radius and tibia.
(8) Androgen-deprivation therapy or surgery to
treat prostate cancer may result in hypogonadism, which is
associated with lower BMD.
(50,51)
The relationship between poor neuromuscular function and
lower vBMD has been documented in several studies.
(1,24,52)
Although the mechanism for this association is not entirely clear,
it may be due to the lower skeletal loading that occurs as a result
ofhavingweakermuscles.
(53)Lowergripstrength wasassociated
with lower cortical vBMD at the radius, consistent with past
reportsonaBMD
(1)andvBMD
(23)inJapanesemen.Ourstudyalso
foundanegativeassociationbetweenusingarmstostandfroma
chair and lower trabecular vBMD, similar to a study in this cohort
on aBMD.
(1)
Our multivariable models explained up to 10% of the
variance in trabecular vBMD and up to 9% of the variance in
cortical vBMD. These estimates are slightly lower than reports
on aBMD
(1,9,13) but compare well with similar studies on
vBMD
(8,11,20,26) in men. A possible explanation for this
observation may be that aBMD is a combination of density,
size, and geometry of both cortical and trabecular bone,
whereas vBMD in our study reflects the density of the voxels in
the cortical or trabecular bone. These results suggest that
there are unknown factors, possibly genetic, related to vBMD
in older men that we have yet to identify. Fewer correlates
were identified for trabecular vBMD of the radius when
compared with tibial trabecular vBMD. The tibia is a major
weight-bearing site compared with the radius, so variables
such as weight and physical function may exert a greater
influence on vBMD.
This study had some potential limitations. Based on the cross-
sectional nature of this study design, causality cannot be
established because we are unable to determine temporal
relationships between the variables. Many of the variables were
collected through self-report, so there was potential for recall
bias resulting in misclassification. African Americans are known
to have higher aBMD
(1,55) and central vBMD
(56) than whites. It is
likely that the small number of African Americans (1.4%) in our
sample reduced our potential to detect an association. Other
findings also may have been affected by lower power (eg,
current smokers: 2.9%). Despite statistical significance, the
clinical significance of some of the findings is questionable
owing to low percentage differences in vBMD.
In summary, we found that the correlates of trabecular and
cortical vBMD differed in our large cohort of older men. Bones
vary in their composition, with some made primarily of cortical
bone and others that are almost entirely trabecular bone. An
ascertainment of risk factors associated with trabecular and
cortical vBMD may lead to better understanding and preventive
efforts for osteoporosis in men. Our study also adds to the
growing literature on the inverse association between body
weight and cortical vBMD. Longitudinal studies are needed to
better understand the mechanisms underlying these differential
associations.
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